TT: Comparing efficacy between hidroxicloroquina, lopinavir-ritonavir y combination of hidroxicloroquina y azitromicina | Pandemic PACT Tracker

Key facts

Disease
COVID-19
Start & end year
N/A
Known Financial Commitments (USD)
$512,136
Funder
National Institute of Health Carlos III [El Instituto de Salud Carlos III] (ISCIII)
Research Location
Spain
Lead Research Institution
Instituto de Investigación Sanitaria del Hospital La Paz de Madrid (IdiPaz)
Research Priority Alignment
N/A

Research Category
Therapeutics research, development and implementation
Research Subcategory
Clinical trial (unspecified trial phase)
Special Interest Tags
N/A
Study Type
Clinical
Clinical Trial Details
Unspecified
Broad Policy Alignment
Pending
Age Group
Unspecified
Vulnerable Population
Unspecified
Occupations of Interest
Unspecified

Abstract

TT: Comparing efficacy between hidroxicloroquina, lopinavir-ritonavir y combination of hidroxicloroquina y azitromicina